You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
Sanford Health will help validate TruGenomix's TruGen-1 post-traumatic stress disorder test through its Imagenetics clinical genomics program.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
Regeneron Pharmaceuticals is among the new investors, as the bioinformatics company continues to scale up its multiomics platform to meet growing demand.
Including the new round, the maker of software to support precision oncology care and drug discovery has landed nearly $100 million in equity investments to date.
Under the agreement, NeoGenomics will also make a $25 million equity investment in Inivata with an option to buy the company outright.
The funding will support the firm's international market expansion on the heels of the release of Lifebit CloudOS version 2.0 this week.
The funds will be used to support the molecular diagnostics company's growth strategy and for general corporate purposes, MDxHealth said.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.